AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 37249658 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxycitric acid (HCA)
Number of subjects: 81
Study 37249658 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study 37249715 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised Mat Pilates exercise
Number of subjects: 156
Study 37249715 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 156
Study 37249860 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19 vaccination (2 doses)
Number of subjects: 0
Study 37249860 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19 vaccination (3 doses)
Number of subjects: 0
Study 37249860 — intervention group
Group type: EXPERIMENTAL
Intervention: Previous COVID-19 infection
Number of subjects: 0
Study 37249860 — intervention group
Group type: COMPARATOR
Intervention: Unvaccinated NHRs
Number of subjects: 0
Study 37249860 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19 vaccination (2 and 3 doses)
Number of subjects: 0
Study 37250148 — intervention group
Group type: EXPERIMENTAL
Intervention: Entinostat plus exemestane (oral exemestane 25 mg/day)
Number of subjects: 0
Study 37250148 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus exemestane (oral exemestane 25 mg/day)
Number of subjects: 0
Study 37250503 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolvaptan
Number of subjects: 230
Study 37250503 — intervention group
Group type: COMPARATOR
Intervention: Standard of Care (SOC)
Number of subjects: 230
Study 37251062 — intervention group
Group type: EXPERIMENTAL
Intervention: Body-centred practices (body scan and Hatha yoga)
Number of subjects: 104
Study 37251062 — intervention group
Group type: EXPERIMENTAL
Intervention: Mind-centred practices (focused attention and open monitoring meditation)
Number of subjects: 104
Study 37251062 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of both body-centred and mind-centred practices
Number of subjects: 104
Study 37251062 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequence of implementation (mind-centred first, then body-centred)
Number of subjects: 104
Study 37251086 — intervention group
Group type: EXPERIMENTAL
Intervention: UC-former deep learning model
Number of subjects: 768
Study 37251506 — intervention group
Group type: EXPERIMENTAL
Intervention: Tipping Point Program (TPP)
Number of subjects: 1242
Study 37251506 — intervention group
Group type: EXPERIMENTAL
Intervention: Tipping Point Plus Program (TPP+)
Number of subjects: 1242
Study 37251506 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 1242
Study 37251511 — intervention group
Group type: EXPERIMENTAL
Intervention: PSQI Subjective Sleep Quality
Number of subjects: 0
Study 37251511 — intervention group
Group type: EXPERIMENTAL
Intervention: PSQI Use of Sleep Medications
Number of subjects: 0
Study 37251511 — intervention group
Group type: EXPERIMENTAL
Intervention: IFS
Number of subjects: 0
Study 37251624 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flow nasal cannula (HFNC)
Number of subjects: 185
Study 37251624 — intervention group
Group type: COMPARATOR
Intervention: Facemask
Number of subjects: 185
Study 37251625 — intervention group
Group type: EXPERIMENTAL
Intervention: WeChat WeQuit program
Number of subjects: 2000
Study 37251625 — intervention group
Group type: COMPARATOR
Intervention: Control messages
Number of subjects: 2000
Study 37251627 — intervention group
Group type: EXPERIMENTAL
Intervention: Radium-223
Number of subjects: 1465
Study 37251628 — intervention group
Group type: EXPERIMENTAL
Intervention: PD1-19bbz infusion
Number of subjects: 21
Study 37251944 — intervention group
Group type: EXPERIMENTAL
Intervention: Apatinib combined with S-1
Number of subjects: 38
Study 37251979 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronos-expressing vectors (AAV2 vector)
Number of subjects: 0
Study 37252109 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral amoxicillin 750 mg three times daily for 100 days
Number of subjects: 78
Study 37252109 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78
Study 37252116 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitral valve repair (MVR) surgery
Number of subjects: 20
Study 37252116 — intervention group
Group type: EXPERIMENTAL
Intervention: CMR scan including 3D late gadolinium enhancement (LGE) imaging
Number of subjects: 20
Study 37252256 — intervention group
Group type: EXPERIMENTAL
Intervention: Horyzons USA digital platform
Number of subjects: 20
Study 37252616 — intervention group
Group type: EXPERIMENTAL
Intervention: ChAd63-KH vaccine
Number of subjects: 0
Study 37252734 — intervention group
Group type: EXPERIMENTAL
Intervention: MiniMed™ 780G Advanced Hybrid Closed-Loop System with Guardian™ 4 Sensor
Number of subjects: 0
Study 37252770 — intervention group
Group type: EXPERIMENTAL
Intervention: Facilitated Telemedicine
Number of subjects: 0
Study 37252945 — intervention group
Group type: EXPERIMENTAL
Intervention: Ertapenem
Number of subjects: 1032
Study 37252945 — intervention group
Group type: COMPARATOR
Intervention: Class 2 carbapenems
Number of subjects: 1032
Study 37252983 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocoa extract (500 mg of cocoa flavanols per day)
Number of subjects: 3562
Study 37252983 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3562
Study 37253044 — intervention group
Group type: EXPERIMENTAL
Intervention: hCG + biotin (20 mg/day)
Number of subjects: 10
Study 37253044 — intervention group
Group type: COMPARATOR
Intervention: hCG + placebo
Number of subjects: 10
Study 37253044 — intervention group
Group type: EXPERIMENTAL
Intervention: hCG + biotin
Number of subjects: 10
Study 37253139 — intervention group
Group type: EXPERIMENTAL
Intervention: Segesterone Acetate and Ethinyl Estradiol Contraceptive Vaginal System
Number of subjects: 0
Study 37253139 — intervention group
Group type: COMPARATOR
Intervention: Control group (Recent Oral Contraceptive or Hormonal Contraceptive Vaginal Ring Users)
Number of subjects: 0
Study 37253387 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic vacuum therapy (EVT)
Number of subjects: 38
Study 37253412 — intervention group
Group type: EXPERIMENTAL
Intervention: Placental EPO mRNA expression in multiples cohort
Number of subjects: 224
Study 37253412 — intervention group
Group type: EXPERIMENTAL
Intervention: Placental EPO mRNA expression in adolescents cohort
Number of subjects: 224
Study 37253412 — intervention group
Group type: EXPERIMENTAL
Intervention: Placental NCOA4 mRNA expression in multiples cohort
Number of subjects: 224
Study 37253412 — intervention group
Group type: EXPERIMENTAL
Intervention: Placental NCOA4 mRNA expression in adolescents cohort
Number of subjects: 224
Study 37253412 — intervention group
Group type: EXPERIMENTAL
Intervention: Placental ERFE and EPO mRNA expression
Number of subjects: 224
Study 37253489 — intervention group
Group type: EXPERIMENTAL
Intervention: NHS Health Check (NHSHC)
Number of subjects: 27888
Study 37253491 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemo-immunotherapy with camrelizumab and cisplatin (75-80 mg/m2)
Number of subjects: 82
Study 37253493 — intervention group
Group type: EXPERIMENTAL
Intervention: Trio whole-genome sequencing (trio WGS)
Number of subjects: 0
Study 37253497 — intervention group
Group type: EXPERIMENTAL
Intervention: Conscious sedation (CS)
Number of subjects: 188
Study 37253497 — intervention group
Group type: COMPARATOR
Intervention: General anaesthesia (GA)
Number of subjects: 188
Study 37253803 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy of basiliximab with ruxolitinib
Number of subjects: 0
Study 37253803 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 37253902 — intervention group
Group type: EXPERIMENTAL
Intervention: SCP-based counseling intervention with goal-setting
Number of subjects: 20
Study 37253992 — intervention group
Group type: EXPERIMENTAL
Intervention: Home healthcare provided by physician and nurse
Number of subjects: 95831
Study 37253992 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher visit frequency of HHC (> 2 times/month)
Number of subjects: 95831
Study 37253992 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher level of resource utilization group (RUG 4)
Number of subjects: 95831
Study 37253992 — intervention group
Group type: EXPERIMENTAL
Intervention: Cirrhosis as a comorbidity
Number of subjects: 95831
Study 37254058 — intervention group
Group type: EXPERIMENTAL
Intervention: Erector spinae plane block (ropivacaine 0.4% + dexamethasone 4 mg, 20 mL per side at the level of surgery) plus postoperative opioid analgesia
Number of subjects: 30
Study 37254058 — intervention group
Group type: EXPERIMENTAL
Intervention: Erector spinae plane block
Number of subjects: 30
Study 37254058 — intervention group
Group type: COMPARATOR
Intervention: Opioid-based analgesia
Number of subjects: 30
Study 37254149 — intervention group
Group type: EXPERIMENTAL
Intervention: PFB-CEUS
Number of subjects: 179
Study 37254149 — intervention group
Group type: EXPERIMENTAL
Intervention: MP-MRI
Number of subjects: 179
Study 37254149 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid model (PFB-CEUS + MP-MRI)
Number of subjects: 179
Study 37254209 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination antibiotic therapy
Number of subjects: 169
Study 37254209 — intervention group
Group type: COMPARATOR
Intervention: Monotherapy
Number of subjects: 169
Study 37254217 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive geriatric assessment (CGA) by a geriatrician
Number of subjects: 16
Study 37254217 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 16
Study 37254221 — intervention group
Group type: EXPERIMENTAL
Intervention: mHealth exercise intervention (EXCAP)
Number of subjects: 20
Study 37254243 — intervention group
Group type: EXPERIMENTAL
Intervention: Simple low-cost intervention to empower dietary salt reduction, details on dosage and duration not available.
Number of subjects: 0
Study 37254243 — intervention group
Group type: COMPARATOR
Intervention: Control group, details not available.
Number of subjects: 0
Study 37254256 — intervention group
Group type: EXPERIMENTAL
Intervention: SCD-directed therapies (e.g., hydroxyurea, l-glutamine, crizanlizumab, voxelotor)
Number of subjects: 0
Study 37254256 — intervention group
Group type: EXPERIMENTAL
Intervention: CKD-directed therapies (e.g., renin-angiotensin-aldosterone system blockers)
Number of subjects: 0
Study 37254449 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 37254502 — intervention group
Group type: EXPERIMENTAL
Intervention: Carpal tunnel release with ultrasound guidance (CTR-US)
Number of subjects: 149
Study 37254502 — intervention group
Group type: COMPARATOR
Intervention: Mini-open carpal tunnel release (mOCTR)
Number of subjects: 149
Study 37254818 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication review intervention (n=196)
Number of subjects: 408
Study 37254941 — intervention group
Group type: EXPERIMENTAL
Intervention: Abrocitinib
Number of subjects: 0
Study 37254941 — intervention group
Group type: COMPARATOR
Intervention: Dupilumab
Number of subjects: 0
Study 37255163 — intervention group
Group type: EXPERIMENTAL
Intervention: Restrictive ventilatory defect observed in patients with TLC below the lower limit of normal (42/95 patients, 44%).
Number of subjects: 95
Study 37255163 — intervention group
Group type: COMPARATOR
Intervention: Patients without reduced TLC (53 patients).
Number of subjects: 95
Study 37255194 — intervention group
Group type: EXPERIMENTAL
Intervention: YK-1169 (2.5 g, 2-h infusion, every 8 hours for 7 days)
Number of subjects: 0
Study 37255194 — intervention group
Group type: COMPARATOR
Intervention: Cefepime (2 g)
Number of subjects: 0
Study 37255194 — intervention group
Group type: COMPARATOR
Intervention: Avibactam (0.5 g)
Number of subjects: 0
Study 37255194 — intervention group
Group type: EXPERIMENTAL
Intervention: Monte Carlo simulation
Number of subjects: 0
Study 37255247 — intervention group
Group type: EXPERIMENTAL
Intervention: Preconception isoprostanes (8-iso-PGF2α)
Number of subjects: 1228
Study 37255247 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoprostanes at 4 weeks gestation (8-iso-PGF2α)
Number of subjects: 1228
Study 37255277 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital Action Plan (DAP) + Written Action Plan (WAP)
Number of subjects: 247
Study 37255277 — intervention group
Group type: COMPARATOR
Intervention: Written Action Plan (WAP)
Number of subjects: 247
Study 37255277 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital Action Plan (DAP)
Number of subjects: 247
Study 37255689 — intervention group
Group type: EXPERIMENTAL
Intervention: Active intradermal acupuncture group
Number of subjects: 120
Study 37255689 — intervention group
Group type: COMPARATOR
Intervention: Sham intradermal acupuncture group
Number of subjects: 120
Study 37255689 — intervention group
Group type: COMPARATOR
Intervention: Waiting list group
Number of subjects: 120
Study 37255691 — intervention group
Group type: EXPERIMENTAL
Intervention: Full interventional version of the Craving-Manager app (4 weeks, EMA + EMI)
Number of subjects: 274
Study 37255691 — intervention group
Group type: COMPARATOR
Intervention: Restricted version of the Craving-Manager app (4 weeks, only EMA)
Number of subjects: 274
Study 37255729 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapist-led 50-minute mixed exercise program, three times a week for 12 weeks
Number of subjects: 14
Study 37255729 — intervention group
Group type: COMPARATOR
Intervention: Control group treatment as usual
Number of subjects: 14
Study 37255987 — intervention group
Group type: EXPERIMENTAL
Intervention: Lasmiditan
Number of subjects: 0
Study 37255987 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 37256099 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose tadalafil
Number of subjects: 23
Study 37256099 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 37256186 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant Toripalimab (240mg, every 3 weeks) plus double platinum-based chemotherapy
Number of subjects: 55
Study 37256186 — intervention group
Group type: EXPERIMENTAL
Intervention: Thyroid dysfunction (irAE)
Number of subjects: 55
Study 37256186 — intervention group
Group type: EXPERIMENTAL
Intervention: Rash/pruritus (irAE)
Number of subjects: 55
Study 37256186 — intervention group
Group type: COMPARATOR
Intervention: Patients without irAEs
Number of subjects: 55
Study 37256193 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.8ng/kg endotoxin injection
Number of subjects: 0
Study 37256193 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo injection
Number of subjects: 0
Study 37256193 — intervention group
Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 0
Study 37256238 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised high-intensity interval training (3 times weekly for 6 months)
Number of subjects: 150
Study 37256238 — intervention group
Group type: COMPARATOR
Intervention: Lifestyle as usual (control group)
Number of subjects: 150
Study 37256238 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised high-intensity interval training
Number of subjects: 150
Study 37256434 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual freehand SUV assessment
Number of subjects: 14
Study 37256536 — intervention group
Group type: EXPERIMENTAL
Intervention: LAMA/LABA (tiotropium/olodaterol, Respimat)
Number of subjects: 463
Study 37256536 — intervention group
Group type: COMPARATOR
Intervention: TT (treatment group)
Number of subjects: 463
Study 37256558 — intervention group
Group type: EXPERIMENTAL
Intervention: Eptinezumab
Number of subjects: 0
Study 37256558 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 37256578 — intervention group
Group type: EXPERIMENTAL
Intervention: Expedited postoperative activity instructions
Number of subjects: 107
Study 37256578 — intervention group
Group type: COMPARATOR
Intervention: Standard restrictions
Number of subjects: 107
Study 37256598 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous Coronary Intervention (PCI)
Number of subjects: 4394
Study 37256598 — intervention group
Group type: COMPARATOR
Intervention: Coronary Artery Bypass Graft (CABG)
Number of subjects: 4394
Study 37256614 — intervention group
Group type: EXPERIMENTAL
Intervention: Circulating cardiomyocyte cfDNA measured after anthracycline therapy
Number of subjects: 71
Study 37256614 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-anthracycline cardiomyocyte cfDNA level
Number of subjects: 71
Study 37256623 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgeon-palliative care comanagement
Number of subjects: 359
Study 37256623 — intervention group
Group type: COMPARATOR
Intervention: Surgeon-alone management
Number of subjects: 359
Study 37256621 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone (10 days treatment)
Number of subjects: 799
Study 37256621 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 799
Study 37256634 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpersonal support domains
Number of subjects: 0
Study 37256680 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive Content Tuning (ACT) mechanism applied to social network interventions (SNIs) delivering tailored organ donation-related educational content through Facebook.
Number of subjects: 0
Study 37256680 — intervention group
Group type: COMPARATOR
Intervention: Standard social network interventions (SNIs) without the ACT mechanism.
Number of subjects: 0
Study 37256753 — intervention group
Group type: EXPERIMENTAL
Intervention: QoR-15
Number of subjects: 135
Study 37256753 — intervention group
Group type: EXPERIMENTAL
Intervention: SF-8
Number of subjects: 135
Study 37256753 — intervention group
Group type: EXPERIMENTAL
Intervention: QoR-15 and SF-8
Number of subjects: 135
Study 37256861 — intervention group
Group type: EXPERIMENTAL
Intervention: eGFR creatinine
Number of subjects: 38
Study 37256861 — intervention group
Group type: EXPERIMENTAL
Intervention: eGFR cystatin C
Number of subjects: 38
Study 37256861 — intervention group
Group type: COMPARATOR
Intervention: iohexol clearance
Number of subjects: 38
Study 37256861 — intervention group
Group type: EXPERIMENTAL
Intervention: Length of ICU stay
Number of subjects: 38
Study 37256861 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in creatinine-to-cystatin C ratio
Number of subjects: 38
Study 37256863 — intervention group
Group type: EXPERIMENTAL
Intervention: Benznidazole (BNZ) 7.5 mg/kg/d administered in two daily doses for 60 days
Number of subjects: 81
Study 37256863 — intervention group
Group type: EXPERIMENTAL
Intervention: Benznidazole (BNZ) 7.5 mg/kg/d
Number of subjects: 81
Study 37256885 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen therapy (HBOT) using 100% oxygen at a pressure of 2.0-2.4 atmospheres absolute (203-243 kPa) for 90 minutes, five times per week
Number of subjects: 86
Study 37256885 — intervention group
Group type: EXPERIMENTAL
Intervention: Subgroup analysis based on pre-existing respiratory disease, smoking history, and applied treatment pressure
Number of subjects: 86
Study 37256916 — intervention group
Group type: EXPERIMENTAL
Intervention: ALVAC-HIV alone
Number of subjects: 0
Study 37256916 — intervention group
Group type: EXPERIMENTAL
Intervention: AIDSVAX B/E gp120 alone
Number of subjects: 0
Study 37256916 — intervention group
Group type: EXPERIMENTAL
Intervention: ALVAC-HIV + AIDSVAX B/E gp120
Number of subjects: 0
Study 37256916 — intervention group
Group type: EXPERIMENTAL
Intervention: ALVAC-HIV
Number of subjects: 0
Study 37256916 — intervention group
Group type: COMPARATOR
Intervention: Control (RV144 regimen)
Number of subjects: 0
Study 37256976 — intervention group
Group type: EXPERIMENTAL
Intervention: Capivasertib plus fulvestrant
Number of subjects: 708
Study 37256976 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus fulvestrant
Number of subjects: 708
Study 37256976 — intervention group
Group type: EXPERIMENTAL
Intervention: Capivasertib plus fulvestrant (AKT pathway-altered population)
Number of subjects: 708
Study 37256976 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus fulvestrant (AKT pathway-altered population)
Number of subjects: 708
Study 37257121 — intervention group
Group type: EXPERIMENTAL
Intervention: DTwP-IPV-HB-PRP~T
Number of subjects: 459
Study 37257121 — intervention group
Group type: COMPARATOR
Intervention: DTwP-HB-PRP~T+bOPV+IPV
Number of subjects: 459
Study 37257143 — intervention group
Group type: EXPERIMENTAL
Intervention: Blinatumomab plus chemotherapy
Number of subjects: 255
Study 37257143 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 255
Study 37257184 — intervention group
Group type: EXPERIMENTAL
Intervention: Tele-Yoga intervention
Number of subjects: 0
Study 37257193 — intervention group
Group type: EXPERIMENTAL
Intervention: Myeloablative conditioning (MAC) haploBMT with posttransplant cyclophosphamide (PTCy), mycophenolate mofetil, and tacrolimus.
Number of subjects: 32
Study 37257366 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial scoring (IS)
Number of subjects: 15
Study 37257366 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary consensus scoring (CS)
Number of subjects: 15
Study 37257366 — intervention group
Group type: EXPERIMENTAL
Intervention: Determination of awake epochs
Number of subjects: 15
Study 37257366 — intervention group
Group type: EXPERIMENTAL
Intervention: Determination of non-rapid-eye-movement stage 2 (N2) epochs
Number of subjects: 15
Study 37257422 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard steroid eye drops
Number of subjects: 90
Study 37257422 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard steroid eye drops plus vasoconstrictor eye drops and cold compress
Number of subjects: 90
Study 37257422 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced steroids plus vasoconstrictor eye drops and cold compress
Number of subjects: 90
Study 37257422 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 90
Study 37257563 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-Carbohydrate (LC) breakfast
Number of subjects: 121
Study 37257563 — intervention group
Group type: COMPARATOR
Intervention: Low-Fat Control (CTL) breakfast
Number of subjects: 121
Study 37257564 — intervention group
Group type: COMPARATOR
Intervention: SQ-LNS (20 g/d)
Number of subjects: 966
Study 37257564 — intervention group
Group type: COMPARATOR
Intervention: Iron and folic acid until delivery, then placebo
Number of subjects: 966
Study 37257564 — intervention group
Group type: COMPARATOR
Intervention: Multiple micronutrients (MMNs)
Number of subjects: 966
Study 37257905 — intervention group
Group type: EXPERIMENTAL
Intervention: New race-free kidney recipient specific GFR equation
Number of subjects: 15489
Study 37257905 — intervention group
Group type: COMPARATOR
Intervention: Race-free CKD-EPI 2021 equation
Number of subjects: 15489